Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, Follicular
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, Follicular
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, Follicular
Description
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES. MeSH
Hierarchy View
Approved Indicated Drugs (14)
Phase 3 Indicated Drugs (24)
Phase 2 Indicated Drugs (92)
allogeneic hematopoietic stem cells (Hemacord)
allogeneic natural killer cells
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous effector lymphocytes expanded ex-vivo
autologous human tumor-derived hsppc-96
Phase 1 Indicated Drugs (114)
Other Experimental Indicated Drugs (14)
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (69)
Australasian Leukaemia and Lymphoma Group
Azienda Ospedaliera San Giovanni Battista
Blood and Marrow Transplant Clinical Trials Network
Center for International Blood and Marrow Transplant Research
European Organisation for Research and Treatment of Cancer
Fondazione Italiana Diabete Onlus
German Low Grade Lymphoma Study Group
Gruppo Italiano Studio Linfomi
Gruppo Italiano Trapianto di Midollo Osseo
Hoosier Cancer Research Network
HOVON - Dutch Haemato-Oncology Association
Polish Lymphoma Research Group
Royal Liverpool & Broadgreen University Hospitals NHS Truts
Russian Academy of Medical Sciences
The Lymphoma Academic Research Organisation
Organization Involved with Phase 2 Indications (119)
Academic and Community Cancer Research United
Badalona Hospital Germans Trias i Pujol
Beijing Mabworks Biotech Co., Ltd.
British Columbia Cancer Agency
Cancer and Leukemia Group B (CALGB)
Cancer Treatment Centers of America
Cantonal Hospital of St. Gallen
Case Western Reserve University
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Chinese Academy of Medical Sciences
City of Hope National Medical Center
ECOG-ACRIN Cancer Research Group
French Innovative Leukemia Organisation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
Henan University of Traditional Chinese Medicine
Innovent Biologics (Suzhou) Co. Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Memorial Sloan-Kettering Cancer Center
North Central Cancer Treatment Group
Oregon Health and Science University
Ospedale S. Giovanni Bellinzona
People's Liberation Army of China
Shanghai YingLi Pharmaceutical Co. Ltd.
South-Eastern Norway Regional Health Authority
Spanish National Health System
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
The Christie NHS Foundation Trust
Organization Involved with Phase 1 Indications (37)
Organization Involved with Other Experimental Indications (5)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
